24
October 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
Placing to Raise
A$200,000
Argent BioPharma, an innovative
multidisciplinary drug development company within the
biopharmaceutical sector, announces that it has received firm
commitments from a professional and sophisticated investor to raise
A$200,000 (Placement)
through the issue of 666,667 fully paid ordinary shares at A$0.30
per share (Placement
Shares).
Proceeds from the Placement will
support the continuation of the Company's drug development
pipeline, including CannEpil® and CimetrA® in the US and EU markets
and general working capital purposes.
The Placement Shares are to be
issued under the Company's existing placement capacity in
accordance with ASX listing Rule 7.1.
-Ends-
Authorised for release by the board of directors, for
further information please contact:
About Argent
BioPharma
Argent BioPharma Limited (the
"Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative
multidisciplinary drug development Company within the
biopharmaceutical sector. The Company focuses on
multidisciplinary methods with Nanotechnology, developing
multi-target therapies for comprehensive disease management,
especially concerning the Central nervous system ("CNS") and
Immunology treatments.
Follow us through our social media
channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent
BioPharma
Total voting rights
On issue of the Fundraising Shares,
the Company will have 54,272,269
Ordinary Shares in issue, each with one voting
right. Therefore, the Company's total number of Ordinary Shares in
issue and voting rights will be 54,272,269 and
this figure may be used by shareholders from issue of the Placing
Shares as the denominator for the calculations by which they will
determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's
Disclosure Guidance and Transparency Rules.
